Description of the Upcoming Change in Data Analysis for USP Dissolution Performance Verification Tests

ABSTRACT
As part of its evaluation of the performance verification tests used periodically to affirm the integrity of the USP
Performance test when General Chapter Dissolution <711> is relied upon, the Biopharmaceutics Expert Committee of the
Council of Experts, working with staff, decided to change the form of the accept/reject decision from one based on the
result for each tablet to one based on the mean and coefficient of variation of results from a set of tablets. This paper
describes the new approach. The paper also describes an implementation period for the approach, coupled with a period
during which USP will discontinue use of the Salicylic Acid tablet in a performance verification test.